with BSO and staging for ovarian cancer was reported [8] .
As techniques and technologies continue to improve, it will become feasible to perform more and more procedures less invasively. This is never more pertinent than it is in the gynecologic oncology (GON) cancer survivor who often requires the most extensive procedures but will benefit considerably from a quick recovery and minimized morbidity. In this article we will briefly review the applications of, and evidence behind, the MIS in GON, specifically TL, RAL and LESS.
Description of approaches to laparoscopic MIS
Laparoscopy involves the introduction of ports through a patient's abdominal wall to visualize and manipulate the organs in the abdominal cavity. Maintaining awareness of basic anatomic principles, TL allows for multiple different entry points in the abdominal wall, allowing the surgeon freedom to determine the position and size of the trocars depending on the procedure and obstacles anticipated. The rigid instruments usually have one point of torque at the abdominal wall that affords some indirect tactile feedback, but limits the ease with which complex movements are made. The visualization is 2D, potentially limiting the surgeon's understanding of spatial relations. However, the pneumoperitoneum distends the internal abdomen and the angle and proximity of the scope to the pelvic organs, often allowing for excellent visualization.
Minimally invasive surgery (MIS) is one of the most exciting frontiers in medicine. Smaller incisions, more advanced technology and newly acquired surgical skills and techniques allow us to offer improved cosmesis, minimal pain, a quicker recovery and better outcomes. Tarasconi performed the first traditional laparoscopic (TL) removal of an organ, a salpingectomy, in 1975 [1] . Gynecologists continued to push the limits of laparoscopy to perform more advanced procedures and surgeries beyond the scope of gynecology, for example, one gynecologist unpopularly performed the first TL appendectomy [2] . The first TL hysterectomy was performed in 1988 by Harry Reich [3] . For many procedures, MIS is now the standard of care. The American Association of Gynecologic Laparoscopists released a position statement that said "surgeons without the requisite training and skills required for the safe performance of vaginal or laparoscopic hysterectomy [on an appropriate patient] should enlist the aid of colleagues who do or should refer" [4] .
Novel approaches to laparoscopy have been developed, including laparoendoscopic singlesite surgery (LESS) and robotic-assisted laparoscopy (RAL). The first LESS procedure was a bilateral tubal ligation performed by Wheeless in 1969 [5] . Pelosi and Pelosi performed the first LESS appendectomy and LESS supracervical hysterectomy with bilateral salpingoophorectomy (BSO) in 1992 [6, 7] . A robotic approach to gynecologic procedures has become increasingly popular since the first RAL hysterectomy Minimally invasive surgery in gynecologic oncology: a review of modalities and the literature Minimally invasive surgery is one of the newest and most exciting areas of development in procedural medicine. This field shows tremendous potential to increase therapeutic benefit while minimizing some of the painful or dangerous side effects of surgical interventions. Minimally invasive surgery has strong historic ties to the field of gynecology and has come a long way as technology and techniques have improved. This has increasingly allowed the application of laparoscopy to more complex procedures and the treatment of gynecologic malignancies. Three laparoscopic approaches, traditional laparoscopy, robotic assisted laparoscopy and laparoendoscopic single-site surgery are reviewed here. We discuss the basic approaches to these three laparoscopic techniques, and then review their applications in gynecologic oncology. We also touch on the evidence behind outcomes associated with their use.
The TL approach is appropriate in patients who can tolerate insufflation and trendelenberg and who do not require a larger incision for palpation of abdominal contents, removal of a specimen or safe entry.
Robotic assistance can be used for patients who are otherwise TL candidates and can tolerate steep trendelenberg and accommodate four to five abdominal port sites. The midline optic trocar is placed 20-27 cm above the pubic symphysis. Four to five additional trocars are placed laterally to the midline trocar, one remaining open for the bedside human assistant. The robotic system consists of four parts: the surgeon console, the patient side cart, detachable instruments and a 3D visual system. The surgeon sits comfortably at the console and has a 3D view, providing an appreciation for objects in space unique to RAL. The patient side cart accommodates and positions the detachable instruments, each with seven degrees of freedom, enabling versatile and complex movements. Surgeon tremor is filtered out and large movements by the surgeon's hands translate into delicate and precise movements at the site of surgery. The advantages this offers in terms of dexterity, accuracy, visualization, instrumentation and surgeon comfort have caused many to endorse RAL for complex GON procedures [9, 10] . However, RAL is also costly, time consuming, bulky and lacks tactile feedback.
LESS involves a hason-like entry at the base of the umbilicus, an anatomically privileged location remote from most vessels and nerves. Advocates argue that it is safer than laparoscopic approaches that require incisions in multiple sites that are more vulnerable to neurovascular injury. Patients who may not be good candidates for LESS include those with greater than two midline vertical incisions in the past, a non-native umbilicus, such as after an abdominoplasty or panniculectomy, advanced carcinoma, or a uterus larger than 16 weeks in size. Morbidly obese patients can also be challenging. For the cancer surgeon, the larger umbilical incision can accommodate larger masses minimizing drainage and manipulation. This may potentially reduce the risk of spillage and contamination of the peritoneal cavity with malignant cells. Furthermore, it is more amenable to palpation of the abdominal contents via a hand-assisted laparoscopic surgery port or by accommodating the surgeon's fingers into the abdomen or some abdominal contents, such as a loop of bowel, briefly up through the incision. The introduction of multiple instruments through a single incision requires the surgeon to overcome awkward posturing and instrument clashing and learn new techniques such as intracorporeal crossing. Intstruments and ports utilized with LESS are illustrated in Tables 1 & 2 .
Applications of MIS in GON
The data is in favor of TL simple hysterectomies with BSO and pelvic and para-aortic lymph node dissection (PPALND) in the surgical staging of clinically early endometrial cancer. The largest randomized controlled trial to evaluate this was LAP-2, a Gynecologic Oncology Group Study that randomized patients to open or TL endometrial cancer staging and analyzed the safety and quality of life after the procedure. LAP-2 demonstrated improved safety and quality of life in patients who underwent TL staging without any detrimental effect on detection of advanced disease [11, 12] . Given the promising results of TL, one could extrapolate that RAL endometrial cancer staging does similarly well, but there is only observational data to support this. The improved visualization, ergonomics and ease of complex, precise maneuvers have led many to speculate that RAL is associated with fewer conversions and is safer and more effective than TL. This has not yet borne out in randomized trials, which are anxiously awaited.
LESS in the treatment of endometrial cancer is novel and good data is lacking. A recent pilot study reported on 20 patients who underwent LESS hysterectomy and BSO for early endometrial cancer with excellent perioperative outcomes and no conversions; staging was not performed [13] . A matched retrospective cohort study of 90 patients demonstrated similar operating times, hospital stays, complication rates and blood loss for patients who underwent LESS, TL or RAL endometrial cancer staging including hysterectomy, BSO and PPALND when indicated [14] . Larger comparative studies, and hopefully randomized controlled trials, will make any advantages of this technique clear.
A recent review of published data comparing RAL to TL radical hysterectomy (RH) with PPALND for early-stage cervical carcinoma concluded that both procedures are feasible, safe, and adequate, but called for more randomized controlled trials. The authors of this review point out the difficulty interpreting the current data given the small numbers for most RAL procedures and that outcomes may improve as surgeons gain experience with this RAL, RH and staging [15] . The amount of vaginal cuff and parametrial tissue obtained at the time of RH appears to be similar between TL and RAL [16] . Many would argue that the complexity of the procedure would make RAL the preferred MIS approach, but this, again, is still speculation.
Laparotomy for ovarian cancer debulking is commonplace, especially given the extensive nature of most diseases at presentation. However, in well-selected, early-stage disease, attempting an MIS approach is an acceptable approach [17, 18] . While TL debulking is not always feasible, the use of exploratory laparoscopy to diagnose, triage and debulk appropriate patients is an option. In one report of 32 patients with the International Federation of Gynecology and Obstetrics stage 2C or greater ovarian cancer who were evaluated with TL prior to their debulking procedure, 17 patients were laparoscopically debulked, 88.2% of whom were cytoreduced to less than 0.5 cm. Notably, comorbid medical conditions, not technical inability, accounted for the two that were not optimally cytoreduced [19] . The first RAL hysterectomy with BSO on a human was part of a RAL ovarian cancer staging including PPALND and an infracolic omentectomy [8] . In a retrospective case-control analysis comparing TL, RAL and open ovarian cancer debulking, Magrina et al. conclude that RAL or TL is preferable for tumor excision and one additional major procedure, but as more procedures are required for debulking, benefit from a MIS approach is lost and laparotomy is preferred [20] . A LESS approach to surgical treatment of early-stage ovarian carcinoma has been described, but comparative data are not available [21] .
Lymph node dissections are commonplace in the surgical treatment of gynecologic malignancies. Lymph node counts are a common indicator of surgical adequacy. Randomized controlled trial data from LAP-2 demonstrated that while lymph nodes were less likely to be removed in the TL group, TL detects advanced endometrial cancer in patients with early clinical disease at the same rate as laparotomy [11] ; data are otherwise rather inconsistent. The interpretation of lymph node counts obtained in nonrandomized, comparative studies is problematic as these observational studies are riddled with biases owing to a particular surgeon's skill level, preference for a method, the extent to which a disease dictates the approach used, and techniques and technology available at the time of the study. Some comparative studies demonstrate a greater lymph node yield for RAL procedures [22] [23] [24] [25] [26] , others favor an open procedure [27] [28] [29] [30] and others favor TL [31] . Still, many studies have failed to show a difference in numbers of lymph nodes obtained between modalities [9, 20, [32] [33] [34] [35] [36] [37] [38] [39] [40] . Comparative data are considerably lacking, but LESS lymphadenectomies appear to yield similar lymph node counts to other techniques, with one series reporting a median pelvic lymph node count of 14, ranging from seven to 19, and a median para-aortic node count of six, ranging from two to 14 [41] . This may be more challenging in obese patients, but a lateral position with the left flank up has been described as a means to work around this [41] . One recent matched retrospective cohort study reports LESS lymph node yields to be similar to RAL and significantly better than TL [14] . Furthermore, extraperitoneal lymph node dissection has been reported and appears to be feasible and safe both via TL [42] , RAL [43] and LESS [44, 45] . Some of our most extensive procedures can be performed via MIS. Delicate and precise procedures such as fertility-sparing radical trachelectomies or parametrectomies have been performed via advanced laparoscopy and robotics [46, 47] . Even the largest, most extensive procedures have met a MIS approach. Pelvic exenteration for gynecologic malignancy has been described in the literature as feasible to perform via TL [48, 49] or RAL [50] .
Outcome measures of MIS in GON
Observational outcome data should be interpreted with caution. Many of these studies are retrospective or use historic controls, making the influence of changes in practice and outcomes with time being difficult to control for. Furthermore, particularly skilled MIS surgeons, sometimes with more or less training in a given modality, often perform these trials, potentially biasing results. Finally, there is a selection bias that results from the publication process, with success rates more likely to be reported if they are optimistic. Nonrandomized comparative studies are useful for hypothesis generation, but not for drawing conclusions about causality. True differences are elucidated by randomized controlled trials, but these rare studies are cumbersome to perform. Below is a summary of the outcomes data that are available thus far for these three MIS modalities in GON. Table 3 highlights studies comparing RAL and TL in GON.
Success rates & need for conversion
Simple and radical TL and RAL hysterectomies with staging for cancer are now routinely performed. In the LAP-2 trial, in patients with clinical stage 1-2A endometrial cancer, the conversion rate for TL surgical staging to laparotomy was 25.8%, with the most common reason for conversion being visibility [11] . With rare exceptions [39] , most observational studies report a much lower conversion rate of 0.0-6.1% for TL hysterectomies and staging [ 
Postoperative complications
Ref.
Simple hysterectomy and staging for endometrial cancer
Veljovich et al.
-----Not measured - [36] Gehrig et al.
Boggess et al. 
Radical hysterectomy and staging for cervical cancer
Magrina et al.
RAL ------ [51] Estape et al. Tinelli et al.
RAL ------ [33] Ovarian cancer debulking In the hands of skilled laparoscopic surgeons, initial LESS performance data is promising. Performing LESS for benign and malignant gynecologic surgeries, Fader et al. reported a 96% success rate, needing to convert one case to TL for adhesions and to laparotomy in two patients because of metastatic ovarian cancer [21] . LESS for extraperitoneal lymph node dissection has been reported with a success rate of 92.9% [44] . Furthermore, an attractive feature of LESS is that when conversion is needed, the surgeon has a choice between inserting additional ports for TL or extending the umbilical incision to perform an exploratory laparotomy.
Operating times
Studies comparing operating room (OR) times for TL, RAL and open GON surgical staging procedures are consistently inconsistent. For simple hysterectomies and staging for endometrial cancer, most comparative studies favor the RAL approach for OR time [22, 24, 29, 31, 38] , but some have demonstrated no difference [28, 37] , and at least one favors TL [35] . Most of the RH and staging procedures for cervical cancer favor a RAL over TL with regards to OR time [27, 33, 51] , but some studies show no difference [26] . In early ovarian cancer debulking, the data are still limited and inconsistent comparing TL with laparotomy [17, 52] . A retrospective case-control study reported the fastest ovarian cancer debulkings by laparotomy followed by TL and then RAL [20] . Comparative data for OR time for LESS compared with other applications is still incomplete and premature.
Estimated blood loss
The bulk of the endometrial cancer data associates RAL staging with a lower estimated blood loss (EBL) and less blood transfusions compared with open surgery [28, 34, 38] and TL [35, 39] . RAL RH and staging for cervical cancer are associated with less blood loss than laparotomy [23, 26, 27, 30, 32, 40, 51] . However, studies comparing R AL to TL RH are inconclusive with some showing less EBL with R AL [27] , but others showing otherwise [23, 26, 27, 30, 32, 40, 51] . TL staging of apparent early-stage ovarian cancers is associated with a lower EBL than laparotomy [17] . RAL ovarian cancer debulking has been associated with a lower EBL than open surgery, but not TL [20] . Again, LESS data is promising in this regard, but most of the comparative data is in benign gynecology. When retrospectively compared with TL, LESS hysterectomies are associated with less blood loss [53] . A recent randomized controlled trial comparing LESS to TL for benign adnexal disease demonstrated that the LESS approach resulted in one-third the blood loss associated with TL, and that LESS provides an advantage over conventional multi access laparoscopy in terms of postoperative pain and the need for rescue analgesia, with similar perioperative outcomes [54] .
Complication rates
Most data and clinical experience favor MIS for its complication profile compared with laparotomy. Randomized controlled trial data demonstrates similar intraoperative but improved postoperative complication rates with TL endometrial cancer staging compared with laparotomy [11] . Regarding randomized trial data, one could extrapolate from LAP-2 and assume that R AL endometrial cancer staging procedures have fewer complications than laparotomy, and multiple observational studies would support this hypothesis [22, 25, 28, 34, 37, 38] . This has not been demonstrated in studies comparing open surgery, RAL RH and staging for cervical cancer [26, 27, 30, 32, 51 ]. Fewer complications have been observed in small studies of TL treatment for apparent stage 1 adnexal cancers [17] , but this association was not observed in advanced disease [20] .
Comparing various MIS modalities, observational studies have mostly found no differences. Some studies have demonstrated a complication profile favoring RAL over TL hysterectomy, BSO and staging for endometrial cancer [27] [28] [29] 31, 33, 35, 37] , but, more commonly, no difference was observed [22, 24, 26, 39, 51] . Similarly, no difference was seen when comparing TL with RAL for staging of cervical [26, 27, 51] or ovarian cancer [20] .
The complication rate for LESS appears low. In one of the largest series of LESS gynecological procedures to date, a review of 74 women who underwent LESS for benign or early-stage cancer, there were no intra operative complications and only three peri operative complications: a pulmonary embolism, vaginal cuff dehiscence and incisional cellulitis [21] . In benign gynecology, a retrospective study [53] and a randomized controlled trial [54] of LESS have demonstrated no difference in complication rates compared with TL.
Incisional complications
After primary laparotomy for a gynecologic malignancy, incidence of ventral hernia has been reported to be 8.8% [55] . Incisional hernias have an incidence of 0.2-3.1% after major TL procedures [56] . One criticism of the LESS approach has been that the larger umbilical incision may put patients at higher risk for umbilical hernia formation [57] . Thus far, umbilical hernias after LESS seem to be rare and comparable to TL, with a reported incidence of 2.4% [58] . While there are some retrospective data that incisional bowel herniation after laparoscopy tends to occur through ports >10 mm in size [59] , there is no evidence that one 1-4 cm incision places the patient at more or less risk for incisional hernia than multiple trocar sites, often including at least one >10 mm. The slightly larger incision may convey risk or allow for a more secure closure. In lieu of stronger comparative data, it seems reasonable to conclude that MIS approaches overall are associated with a lower incisional hernia rate than laparotomy. The ideal MIS modality remains to be determined.
Port-site metastases have an incidence of 0.97-2.3%, but are more likely in women undergoing surgery for disseminated carcinoma, especially in the setting of ascites, synchronous intrabdominal metastases and advanced or recurrent disease [60] [61] [62] . Theoretical causes and means of preventing this have been reviewed, but have not been evaluated in clinical trials [61] . In theory, the risk is minimized with fewer ports, but again, prospective trials comparing TL, RAL and LESS are called for.
Enhanced cosmesis
One of the market-driving forces behind MIS in all surgical fields, including GON, is enhanced cosmesis. Patients have a better body image after laparoscopy than open endometrial cancer staging [12] . Proponents of LESS claim that the single incision at the umbilicus is cosmetically preferable to multiple incisions. Early critics pointed out that this was based on surgeon assumption not patient preferences [57] . However, recent survey data and randomized controlled trial data from outside of GON indicate that patients and surgeons do prefer LESS scars [54, 63] . Further comparative evaluations of the cosmetic outcomes of RAL, TL and LESS in GON are anxiously anticipated.
Improved pain profiles
Improvement in postoperative pain has been demonstrated with the utilization of MIS in GON. Again, the LAP-2 randomized controlled trial data confirm that laparoscopically staged endometrial cancer patients experience less pain than their counterparts that undergo laparotomy [12] . Utilizing one incision in the thinnest portion of the abdominal wall, LESS continues to be promising in this regard. Very low pain scores and narcotic needs have been reported after LESS procedures for both benign and malignant gynecologic disease, with no need for home narcotics being reported by one-third of cancer patients [21] . The benign gynecology literature favors LESS over TL, with favorable pain profiles reported for LESS in a retrospective review of laparoscopically assisted vaginal hysterectomy as well as a randomized controlled trial of adnexal surgery [54, 64] . Randomized controlled trials from the cholecystectomy literature support these results [65, 66] .
Quicker healing
The clinical recovery of patients after MIS is remarkable compared with those who undergo open surgery. Clinical stage 1-2A endometrial cancer patients who were randomized to TL staging had shorter hospital stays, better functioning and quality of life, and earlier resumption of normal activities and return to work in the 6 weeks postoperatively compared with their counterparts who underwent laparotomy [11, 12] . Observational retrospective studies repeatedly demonstrate shorter hospital stays associated with RAL simple and radical hysterectomies compared with open surgery [22, 23, [25] [26] [27] 29, 30, 32, 34, 37, 38, 40, 51] . Compared with TL, some observational studies have demonstrated shorter hospital stays for RAL simple and RH with staging [22, 24, 27, 29, 31, 39] , but some studies have not demonstrated a significant difference [26, 28, 33, 35, 37, 51] . Small observational studies have associated shorter hospital stays with TL and RAL compared with open ovarian cancer debulking procedures [17, 18, 20] .
Again, data in GON are needed, but in the benign gynecology literature LESS is promising in this regard. LESS hysterectomies are retrospectively associated with shorter hospital stays and earlier diet intake compared with TL [53] . A randomized controlled trial of LESS compared with TL adnexal surgery for benign disease failed to demonstrate any difference in hospital stay, but was small and not powered to demonstrate this [54] . Further comparative data are warranted.
Cancer-related outcomes
Given the novelty of many of these approaches, good long-term data are sparse. It will be some time until long-term outcomes data from the LAP-2 randomized controlled trial are available. Hopefully, minimizing morbidity and enhancing recovery from operative treatment of gynecologic malignancies will improve overall health and enable the cancer survivor to receive adjuvant therapy quicker. However, we must keep in mind that as long as the data are limited, we could be performing harm unknowingly.
In a promising retrospective analysis of clinical stage 1 ovarian cancer patients, patients who underwent TL surgical staging had better shortterm postoperative outcomes, no difference in outcomes at 17 months and a shorter interval to adjuvant therapy [18] . However, this was followed by a report later in the same year demonstrating that two patients in the TL group with stage 1A disease recurred and one died of recurrence, causing them to question the oncologic safety of laparoscopic staging [52] . Another recent retrospective study comparing TL, RAL and open RH and staging for early cervical carcinoma demonstrated improved OR times and EBL for RAL; however, they also reported five cervical cancer recurrences with one cervical cancer-related death in the robot-assisted group and no recurrences in the laparoscopy and laparotomy group [27] .
It is difficult to interpret these concerning but potentially aberrant results in these small studies. Prospective and randomized trials are necessary to further clarify any real benefit, or harm, conveyed by any MIS approach to the GON patient. Long-term outcome data from LAP-2 and further randomized controlled trials comparing MIS approaches to laparotomy and to each other are eagerly anticipated.
Conclusion & future perspective
MIS has come a long way, both in terms of the technology and approaches available and the skill level of the surgeons who practice it. There are great data available that short-term outcomes are better for early-stage endometrial cancer thanks to the LAP-2 randomized controlled trial. While we extrapolate these results to our other malignancies, further studies such as this one are needed to evaluate MIS approaches in other early-stage gynecologic cancers and in more advanced disease. There is currently an ongoing randomized controlled trial comparing RAL, TL and open RH and staging for cervical cancer [67] . Well-designed randomized controlled trials are the only way we will meaningfully be able to understand the benefits or harms conveyed by MIS procedures compared with open surgery or to each other.
In GON, MIS holds promise for real improvement in outcomes, allowing patients to heal and proceed with adjuvant therapy faster, while tumor burden is still low. Robotics has been embraced by the field, and LESS is an exciting option just beginning to be explored. Thoughtful analysis of cost and savings of various techniques taking into account equipment are needed.
While attempting to better understand the procedures available, new techniques are also on the horizon. The first robotic-assisted LESS hysterectomy and BSO for risk reduction has been reported [68] . This same author has described a cadaveric model for robotic LESS to perform a variety of other GON procedures, including hysterectomy, BSO, modified RH and PPALND dissections [69] . Robotic applications of LESS show promise to eliminate many ergonomic and technical limitations by allowing the surgeon to avoid the awkward posturing and, if desired, correct for on screen handedness when they are intraperitoneally crossed, which may improve performance [70] . Furthermore, we need to continue to evaluate MIS approaches to more advanced procedures, as feasibility may improve as our techniques and technologies do.
MIS shows tremendous promise in GON. We must continue to evaluate current techniques comparatively and develop new ones. The implementation of MIS techniques can help patients heal faster and with less morbidity. Maximizing mobility and quality of life and minimizing the time to recovery and adjuvant therapy is paramount in the field of GON. Further research is needed to determine if these improved outcomes will produce long-term improvements in outcomes. (CA, USA) . AN Fader is a consultant for Applied Medical (CA, USA). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
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Executive summary
Background • Laparoscopy has strong historic roots in gynecologic surgery; robotic-assisted laparoscopy (RAL) is becoming increasingly popular and laparoendoscopic single-site surgery (LESS) is a newly re-embraced approach to laparoscopy. • Minimally invasive surgery (MIS) is becoming the standard of care.
Description of approaches to laparoscopic MIS
• Traditional laparoscopy (TL) allows for flexibility in terms of size and location of trocar placement and tactile feedback, but can be limited by a 2D view, rigid instruments and challenges accomplishing complex maneuvers. • RAL offers a 3D view, surgeon comfort, ease of precise and complex surgical maneuvers but is costly, time consuming, bulky and lacks tactile feedback. • LESS involves the insertion of instruments through a single 1-4-cm incision at the umbilicus; surgeons must adopt novel laparoscopic skills and adapt to awkward posturing and instrument clashing.
Applications of MIS in gynecologic oncology
• Excellent randomized controlled trial data supports the use of TL over laparotomy in the surgical staging of clinically early endometrial cancer. Support for RAL or LESS approaches is based on extrapolation from this and warrants further comparative research. • Further randomized prospective trials are needed to determine the optimal surgical approach to cervical and ovarian cancer. 
Outcome measures of MIS in gynecologic oncology

